Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05288348 · ClinicalTrials.gov registry record · Phase 3

DSUVIA Early Evaluation of Pain Trial

A Phase 3 study of Traumatic Injury, sponsored by Frank Guyette.

Completed
Registry status
Phase 3
Development phase
150
Enrollment target
1
Study location

NCT05288348 is a Phase 3 study of Traumatic Injury that has completed, run by Frank Guyette. The registered enrollment target is 150 participants, below the 418-participant average among 7 other Traumatic Injury trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05288348, a Phase 3 study of Traumatic Injury, has completed, sponsored by Frank Guyette.

COMPLETED
Registry status
Phase 3
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

Randomized, interventional trial of Emergency Department (ED) administration of DSUVIA (sufentanil) versus standard care pain management comparing pain treatment outcomes in injured patients with moderate to severe pain

Conditions Studied

Interventions

  • DRUG Sufentanil 30 MCG Sublingual Tablet
  • DRUG standard care pain treatment

Study Locations (1)

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-08-05
Est. Completion 2024-01-21
Phase Phase 3

Sponsor

Frank Guyette

1 total trials

What the Registry Record Tells You About NCT05288348

The ClinicalTrials.gov registry entry for NCT05288348 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 418-participant average among 7 other Traumatic Injury trials with a reported enrollment target (64% lower). The listed sponsor is Frank Guyette, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Traumatic Injury appearing as the primary indexed condition, and to 2 interventions - of which Sufentanil 30 MCG Sublingual Tablet is the first listed.

NCT05288348 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05288348 about?

NCT05288348 is a clinical study titled "DSUVIA Early Evaluation of Pain Trial". Randomized, interventional trial of Emergency Department (ED) administration of DSUVIA (sufentanil) versus standard care pain management comparing pain treatment outcomes in injured patients with moderate to severe pain

What is the current status of trial NCT05288348?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2022-08-05. Estimated completion is 2024-01-21.

What conditions does trial NCT05288348 study?

This clinical trial studies the following conditions: Traumatic Injury.

What interventions are being tested in trial NCT05288348?

The interventions under investigation include: Sufentanil 30 MCG Sublingual Tablet (DRUG), standard care pain treatment (DRUG).

Who is sponsoring clinical trial NCT05288348?

This trial is sponsored by Frank Guyette, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05288348 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Traumatic Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.